📊 HBIO Key Takeaways
Is Harvard Bioscience Inc. (HBIO) a Good Investment?
Harvard Bioscience is experiencing severe financial distress with a $48.6M operating loss and $56.7M net loss despite solid 57.7% gross margins, indicating critical execution or operational structure failures. The company's 2.61x debt-to-equity ratio combined with negative interest coverage ratio (-13.5x) and declining revenue (-8.1% YoY) creates acute refinancing and solvency risk.
Healthy gross margins and positive free cash flow suggest an underlying cash-generative core, but steep revenue decline and severe operating losses point to unresolved structural issues. High leverage, thin equity, and negative interest coverage elevate solvency and dilution risk if a turnaround does not materialize.
Why Buy Harvard Bioscience Inc. Stock? HBIO Key Strengths
- Gross margin of 57.7% demonstrates strong underlying product unit economics and pricing power
- Positive operating cash flow of $6.7M and free cash flow of $5.5M despite losses shows the business generates cash
- Current ratio of 2.20x indicates adequate short-term liquidity to meet immediate obligations
- Robust gross margin at 57.7%
- Positive operating cash flow and FCF with low capex
- Adequate liquidity with 2.20x current ratio
HBIO Stock Risks: Harvard Bioscience Inc. Investment Risks
- Massive operating loss of -$48.6M with -56.1% operating margin indicates severe cost structure misalignment or demand collapse
- Very high leverage with 2.61x debt-to-equity ratio and $35.9M long-term debt against only $13.7M stockholders equity creates refinancing risk
- Negative interest coverage ratio of -13.5x means operating income cannot cover interest payments, threatening debt service capability
- Revenue declining 8.1% YoY combined with worsening losses suggests structural business deterioration rather than cyclical downturn
- Stockholders equity of only $13.7M represents only 17% of total assets, leaving minimal buffer for further losses
- Severe and worsening profitability (operating margin -56.1%, net margin -65.5%)
- High leverage (D/E 2.61x) and negative interest coverage (-13.5x)
- Revenue contraction (-8.1% YoY) indicating demand or execution headwinds
Key Metrics to Watch
- Operating margin improvement trajectory (currently -56.1%) and return to profitability
- Revenue stabilization and growth resumption (currently declining)
- Debt refinancing activity and covenant compliance given negative interest coverage
- Operating expense reduction and restructuring progress
- Cash burn rate and runway relative to debt obligations
- Operating margin trajectory
- Interest coverage improvement
Harvard Bioscience Inc. (HBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.20x current ratio provides a solid financial cushion.
HBIO Profit Margin, ROE & Profitability Analysis
HBIO vs Industrial Sector: How Harvard Bioscience Inc. Compares
How Harvard Bioscience Inc. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Harvard Bioscience Inc. Stock Overvalued? HBIO Valuation Analysis 2026
Based on fundamental analysis, Harvard Bioscience Inc. shows some fundamental concerns relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Harvard Bioscience Inc. Balance Sheet: HBIO Debt, Cash & Liquidity
HBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Harvard Bioscience Inc.'s revenue has declined by 21% over the 5-year period, indicating business contraction. The most recent EPS of $-0.28 indicates the company is currently unprofitable.
HBIO Revenue Growth, EPS Growth & YoY Performance
HBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $20.6M | -$1.2M | $-0.03 |
| Q2 2025 | $20.5M | -$2.3M | $-0.05 |
| Q1 2025 | $21.8M | -$4.7M | $-0.11 |
| Q3 2024 | $22.0M | -$1.2M | $-0.03 |
| Q2 2024 | $23.1M | -$358.0K | $-0.01 |
| Q1 2024 | $24.5M | $622.0K | $0.01 |
| Q3 2023 | $25.4M | -$1.2M | $-0.03 |
| Q2 2023 | $28.8M | -$358.0K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Harvard Bioscience Inc. Dividends, Buybacks & Capital Allocation
HBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Harvard Bioscience Inc. (CIK: 0001123494)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HBIO
What is the AI rating for HBIO?
Harvard Bioscience Inc. (HBIO) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HBIO's key strengths?
Claude: Gross margin of 57.7% demonstrates strong underlying product unit economics and pricing power. Positive operating cash flow of $6.7M and free cash flow of $5.5M despite losses shows the business generates cash. ChatGPT: Robust gross margin at 57.7%. Positive operating cash flow and FCF with low capex.
What are the risks of investing in HBIO?
Claude: Massive operating loss of -$48.6M with -56.1% operating margin indicates severe cost structure misalignment or demand collapse. Very high leverage with 2.61x debt-to-equity ratio and $35.9M long-term debt against only $13.7M stockholders equity creates refinancing risk. ChatGPT: Severe and worsening profitability (operating margin -56.1%, net margin -65.5%). High leverage (D/E 2.61x) and negative interest coverage (-13.5x).
What is HBIO's revenue and growth?
Harvard Bioscience Inc. reported revenue of $86.6M.
Does HBIO pay dividends?
Harvard Bioscience Inc. does not currently pay dividends.
Where can I find HBIO SEC filings?
Official SEC filings for Harvard Bioscience Inc. (CIK: 0001123494) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HBIO's EPS?
Harvard Bioscience Inc. has a diluted EPS of $-1.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Harvard Bioscience Inc. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HBIO stock overvalued or undervalued?
Valuation metrics for HBIO: ROE of -412.8% (sector avg: 15%), net margin of -65.5% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy HBIO stock in 2026?
Our dual AI analysis gives Harvard Bioscience Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HBIO's free cash flow?
Harvard Bioscience Inc.'s operating cash flow is $6.7M, with capital expenditures of $1.3M. FCF margin is 6.3%.
How does HBIO compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -65.5% (avg: 10%), ROE -412.8% (avg: 15%), current ratio 2.20 (avg: 1.8).
Is Harvard Bioscience Inc. carrying too much debt?
HBIO has a debt-to-equity ratio of 2.61x, which is above the Industrial sector average of 0.7x. However, the current ratio of 2.20 suggests adequate short-term liquidity.